Welcome to our dedicated page for Lensar news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on Lensar stock.
LENSAR, Inc. (Nasdaq: LNSR) is a commercial-stage medical device and global medical technology company focused on advanced laser systems for the treatment of cataracts and the management of astigmatism. News about LENSAR often centers on its ALLY Robotic Cataract Laser System, financial performance, and the company’s pending acquisition by Alcon Research, LLC.
Regular earnings releases provide updates on quarterly revenue, procedure volumes performed on LENSAR’s installed base of laser systems, and the mix between system sales and recurring revenue from procedures, leases, and service. These reports also discuss non-GAAP metrics such as EBITDA and Adjusted EBITDA, along with commentary on operational initiatives and utilization of the ALLY system in the United States and abroad.
Another recurring news theme is corporate and capital markets activity. LENSAR has announced a definitive merger agreement under which Alcon intends to acquire the company, including the ALLY Robotic Cataract Laser Treatment System, Streamline software technology, and the LENSAR legacy laser system. Subsequent updates describe stockholder approval of the merger proposal and ongoing regulatory review, including interactions with the U.S. Federal Trade Commission.
LENSAR also issues announcements related to equity compensation, such as inducement grants of restricted stock units and stock options to newly hired non-executive employees under its Employment Inducement Incentive Award Plan. These items provide insight into hiring and compensation practices. Investors and observers who follow LNSR news can use this page to review earnings releases, merger-related developments, and governance and compensation updates in one place.
LENSAR (Nasdaq: LNSR) reported fourth-quarter and full-year 2025 results, highlighting recurring revenue of $46.3 million for the year, a 15% increase versus 2024, and recurring revenue representing 79% of total revenue for both Q4 and FY2025. ALLY installed base reached approximately 200 systems (a 48% increase year-over-year) with a backlog of 13 systems and total combined installed base of ~435 systems, up 13% year-over-year.
Worldwide procedure volume rose ~22% in 2025. Q4 total revenue was $16.0 million; net loss was $1.5 million for Q4 2025. Cash and investments totaled $18.0 million at year-end. The company and Alcon executed a termination agreement under which LENSAR will retain a $10.0 million merger deposit.
Alcon (SIX/NYSE: ALC) and LENSAR (NASDAQ: LNSR) agreed to terminate their previously announced merger. The companies said the nearly one-year regulatory review and the FTC's opposition made the transaction unattractive to pursue.
Alcon cited delay and associated costs and reaffirmed its commitment to advancing cataract surgery technologies.
LENSAR (Nasdaq: LNSR) announced termination of its merger agreement with Alcon Research, LLC, after the Federal Trade Commission indicated it intends to seek to enjoin the acquisition. The companies mutually agreed to end the deal because required U.S. regulatory approvals were unlikely by the April 23, 2026 outside date (or extended July 23, 2026).
The company will retain the $10.0 million deposit from the merger agreement and plans to report fourth quarter and full-year 2025 results and a strategic update on March 31, 2026, including a conference call at 8:30 a.m. ET.
LENSAR (Nasdaq: LNSR) provided an update on its pending acquisition by Alcon. The companies remain engaged with the U.S. Federal Trade Commission after receiving a Second Request for additional information and documentary material.
In light of the ongoing review, LENSAR currently expects the transaction to close in the first half of 2026, subject to satisfaction of closing conditions including FTC regulatory approval.
LENSAR (Nasdaq: LNSR) reported 3Q 2025 results and a business update on Nov 6, 2025. Revenue was $14.3M, up 6% from 3Q 2024, driven by ~11% higher procedure volume. The company placed 18 ALLY Systems in the quarter, increasing the ALLY installed base to ~185 (up 77% YoY) and total laser installed base to ~425 (up 20% YoY); backlog includes 18 ALLY Systems pending installation.
Expenses and results: SG&A rose to $12.0M (98% increase) largely from ~$5.3M of acquisition-related costs for the proposed Alcon merger; net loss was $3.7M (loss per share $0.31). Cash and investments were $16.9M at Sept 30, 2025. The company expects the Alcon transaction to close in Q1 2026, subject to FTC review.
LENSAR (Nasdaq: LNSR) announced the granting of inducement awards to three newly-hired non-executive employees. The compensation package consists of 660 restricted stock units (RSUs) in total, approved by the independent members of LENSAR's board of directors.
The RSUs were granted on September 2, 2025, under LENSAR's 2024 Employment Inducement Incentive Award Plan. Each RSU represents one share of common stock and will vest in four equal annual installments, contingent upon continued employment with the company through each vesting date.
LENSAR (NASDAQ:LNSR) reported strong Q2 2025 results, highlighted by significant growth in its ALLY Robotic Cataract Laser Systems business. The company achieved total revenue of $13.9 million, up 10% year-over-year, driven by a 23% increase in worldwide procedure volumes.
Key highlights include 18 new ALLY Systems placements in Q2 with an additional 18 systems in backlog. The ALLY installed base grew 107% year-over-year to 165 systems, while the total combined installed base increased 23% to 410 systems. The company's recurring revenue reached 82% of total revenue.
LENSAR reported a net loss of $1.8 million ($0.15 per share), improved from a $9.0 million loss in Q2 2024. The company ended the quarter with $20.3 million in cash and investments. Notably, shareholders overwhelmingly approved the proposed merger with Alcon, with over 99% of votes in favor, expected to close by year-end.
LENSAR (Nasdaq: LNSR) announced the granting of inducement awards to three newly-hired non-executive employees. The compensation package consists of an aggregate of 660 restricted stock units (RSUs), approved by the independent members of LENSAR's board of directors.
The RSUs were granted on July 1, 2025, under LENSAR's 2024 Employment Inducement Incentive Award Plan. Each RSU represents one share of common stock and will vest in four equal annual installments, contingent upon continued employment with the company through each vesting date.